Corcept Therapeutics is trading at $121.11, up 4.19%, with no clear company-specific catalyst identified for the October 5 move. - Its latest listed releases were September 23 and September 18; an October 5 Zacks mention was an analyst-blog feature, not a reported new catalyst. - The S&P 500 was up 0.59% and Nasdaq Composite up 0.96%, a positive backdrop that may be contributing but does not establish the stock’s cause. - No volume information was provided.